4D printing esophageal stent and preparation method thereof

The esophageal stent fabricated using 4D printing technology employs a biomimetic water lily hollow structure and a core-shell drug-loaded fiber membrane, solving the problems of displacement and stenosis associated with existing stents. This enables long-term sustained drug release and prevents esophageal restenosis, thereby improving treatment efficacy and safety.

CN120827647APending Publication Date: 2025-10-24HARBIN INST OF TECH
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202510975659.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-15
Publication Date
2025-10-24

AI Technical Summary

Technical Problem

Existing esophageal stents have problems such as displacement, narrowing, and difficulty in removal when treating esophageal strictures, which affect the treatment effect and threaten patient safety, and cannot effectively prevent esophageal restenosis in the long term.

Method used

An esophageal stent was fabricated using 4D printing technology. The stent body adopts a biomimetic water lily hollow structure with barbs at both ends. It uses shape memory polymers and core-shell structured drug-loaded fiber membranes. The stent body is composed of shape memory polylactic acid, tributyl citrate, and poly(dibutyl adipate/terephthalate). The drug-loaded fiber membrane contains anti-scarring drugs and is prepared by electrospinning.

Benefits of technology

This improved the stent's compressive strength and anti-slip performance, enabling long-term, uniform, and sustained drug release, reducing the risk of restenosis, and ensuring patient safety and treatment effectiveness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120827647A_ABST
    Figure CN120827647A_ABST
Patent Text Reader

Abstract

The invention provides a 4D printing esophageal stent and a preparation method thereof. The esophageal stent comprises a stent main body and a drug-loaded fiber membrane with a core-shell structure, the stent main body is a tubular stent composed of a bionic water lily hollow structure; the diameters of the head end and the tail end of the support body are larger than the diameter of the middle section, and barb structures are arranged on the outer surfaces of the head end and the tail end. The stent main body is a biodegradable shape memory polymer; the drug-loaded fibrous membrane is positioned on the outer surface of the middle section of the stent main body, and the drug-loaded fibrous membrane contains drugs. The 4D printing esophageal stent provided by the invention has excellent compressive bearing capacity and anti-slip capacity, and the drug-loaded fibrous membrane can avoid esophageal restenosis through long-term uniform slow release of drugs, so that the life safety of a patient can be further guaranteed.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of medical material manufacturing, in particular to a 4D-printed esophageal stent and a preparation method thereof. BACKGROUND

[0002] Esophageal stenosis mainly refers to the stenosis of the esophageal lumen caused by diseases of the esophagus itself or complications, which is divided into benign stenosis and malignant stenosis. Esophageal benign stenosis is caused by various reasons leading to non-tumor chronic injury and fibrosis of the esophagus, such as misusing corrosive substances, radiotherapy damage, postoperative anastomotic stenosis of the esophagus, gastroesophageal reflux, etc., thereby causing clinical symptoms such as dysphagia, pain when swallowing, weight loss, food reflux after meals, nutritional imbalance and aspiration pneumonia, affecting the quality of life of patients, and even endangering the lives of serious patients, which has brought huge economic and medical burden to the society. How to effectively prevent and treat esophageal benign stenosis has become a medical problem to be solved.

[0003] In recent years, esophageal stent implantation as a safe and effective palliative treatment has attracted attention. For some patients with refractory benign esophageal stenosis, when the expansion effect is poor, combined treatment through esophageal stent implantation can effectively reduce the risk of esophageal stenosis and relieve the chronic inflammatory process and remodeling of scar tissue, so that the esophagus can maintain patency. At present, the stents commonly used for the treatment of benign esophageal stenosis are self-expanding metal stents or self-expanding plastic stents, which may have displacement, stenosis, and difficulty in removal, thereby affecting the treatment effect or the safety of patients, and at the same time, these conditions may cause the stent to be unable to be permanently implanted in the body. Therefore, there is an urgent need for a new esophageal stent to solve the above problems. SUMMARY

[0004] The present application provides a 4D-printed esophageal stent and a preparation method thereof. The 4D-printed esophageal stent has excellent compression bearing capacity and anti-slippage ability, and the drug-loaded fiber membrane can avoid esophageal restenosis by long-term uniform drug release, thereby ensuring the safety of patients.

[0005] In a first aspect, the present application provides a 4D-printed esophageal stent, which comprises a stent body and a drug-loaded fiber membrane with a core-shell structure; the stent body is a tubular stent composed of a bionic lotus hollow structure; the diameters of the first end and the last end of the stent body are greater than that of the middle segment, and the outer surfaces of the first end and the last end are provided with barb structures; the stent body is a biodegradable shape memory polymer; the drug-loaded fiber membrane is located on the outer surface of the middle segment of the stent body, and the drug-loaded fiber membrane contains a drug.

[0006] Preferably, the shape memory polymer is prepared by adding polybutylene adipate / terephthalate and tributyl citrate to shape memory polylactic acid.

[0007] More preferably, the amount of polybutylene adipate / terephthalate is 2-8 wt% of the amount of shape memory polylactic acid, and the amount of tributyl citrate is 9-11 wt% of the amount of shape memory polylactic acid.

[0008] Preferably, the shell layer of the drug-loaded fiber membrane is polycaprolactone, and the core layer is ethyl cellulose.

[0009] Preferably, the drug-loaded fiber membrane comprises an anti-scarring drug.

[0010] More preferably, the content of the anti-scarring drug is 1-5 wt% of the core layer of the drug-loaded fiber membrane.

[0011] Preferably, the biomimetic lotus hollow structure takes a regular hexagon as a frame, and the regular hexagon is divided into a plurality of rhombuses and a plurality of triangles.

[0012] More preferably, the side length of the regular hexagon is 1 / 12-1 / 3 of the circumference of the stent body.

[0013] Preferably, the regular hexagon is divided into 10 rhombuses and 4 triangles, and the regular hexagon is an axisymmetric figure.

[0014] Preferably, the acute internal angle of the rhombus is 50-70°.

[0015] Preferably, the diameter of the head end is the same as the diameter of the tail end, and the diameter of the head end and the tail end is 2-4 mm larger than the diameter of the middle section.

[0016] Preferably, the length of the barb structure is 0.5-1.5 mm, and the barb angle is 40-50°.

[0017] More preferably, 9-18 barb structures are arranged along the circumference of the head end and the tail end.

[0018] Preferably, the head end and the tail end are further provided with a developing marker.

[0019] More preferably, the developing marker is one or more of gold, tungsten, platinum-iridium alloy, and nickel-titanium alloy.

[0020] Preferably, the esophageal stent comprises an initial shape and a temporary shape, the volume of the initial shape is larger than the volume of the temporary shape; the esophageal stent is deformed from the temporary shape to the initial shape by thermal driving stimulation.

[0021] In a second aspect, the present application provides a preparation method of the 4D-printed esophageal stent of the first aspect, the preparation method comprising:

[0022] (1) design a three-dimensional structural model of an esophageal stent;

[0023] (2) determine a shape memory polymer used for the esophageal stent, prepare a printing wire material from the shape memory polymer, print the printing wire material by using a 4D printing technology, and obtain a stent body with an initial shape after forming;

[0024] (3) prepare a drug-loaded fiber membrane with a core-shell structure by using an electrospinning method, and place the drug-loaded fiber membrane on the outer surface of the middle section of the stent body to obtain the 4D printed esophageal stent.

[0025] Preferably, in step (2), polybutylene adipate / terephthalate, shape memory polylactic acid and tributyl citrate are added to a screw extruder, mixed and extruded to obtain the printing wire material.

[0026] More preferably, the speed of the screw extruder is 62-65 rpm, and the temperature is 170-180℃.

[0027] Preferably, in step (3), polycaprolactone and a mixed solvent are mixed to obtain a shell spinning solution; ethyl cellulose, an anti-scarring drug and a mixed solvent are mixed to obtain a core spinning solution; the shell spinning solution and the core spinning solution are added to syringes respectively, and the drug-loaded fiber membrane is obtained by using an electrospinning method through coaxial needles; wherein the mixed solvent comprises dichloromethane and dimethylacetamide.

[0028] More preferably, the electrospinning conditions are as follows: the flow rate of the shell spinning solution is 0.6-0.8 mL / h, the flow rate of the core spinning solution is 0.3-0.4 mL / h, the spinning voltage is 18-24 kV, and the spinning distance is 10-20 cm.

[0029] Compared with the prior art, the present application has at least the following beneficial effects:

[0030] (1) The stent body of the 4D printed esophageal stent provided by the present application adopts a bionic lotus hollow structure, is designed with reference to the radial distribution of the leaf vein structure of a lotus, thereby effectively dispersing the pressure received by the stent and improving the pressure resistance of the stent. In addition, the stent body as a whole has a dumbbell-shaped structure with thick ends and a thin middle section, and the outer surfaces of the first end and the last end have barb structures, which effectively improve the anti-slip performance of the esophageal stent.

[0031] (2) The main body material of the 4D printing esophageal stent provided by the application is composed of shape memory polylactic acid, tributyl citrate and polybutylene adipate terephthalate, the addition of tributyl citrate adjusts the glass transition temperature of the material system, so that the deformation temperature is more suitable for human body temperature, and the compatibility between the shape memory polylactic acid and the polybutylene adipate terephthalate is improved, and the common action of the polybutylene adipate terephthalate and the tributyl citrate can effectively improve the toughness and printing performance of the material system, so that the mechanical properties of the material system are more suitable for the human body, and the wear on the affected part is reduced. In addition, the material system enables the 4D printing esophageal stent to have a shape memory function, which is helpful for the minimally invasive implantation of the esophageal stent and reduces the pain of the patient.

[0032] (3) The drug-loaded fiber membrane with a core-shell structure is adopted, the shell layer is polycaprolactone, the core layer is ethyl cellulose, and the core layer contains an anti-scarring drug. The existence of the core-shell structure can realize long-term and uniform release of the drug in the fiber membrane, so as to ensure that the anti-scarring drug can continuously play a role during the use of the esophageal stent, so as to prevent the phenomenon of esophageal restenosis.

[0033] (4) The metal wires with a developing function are further arranged at the two ends of the stent main body, so that the esophageal stent can be avoided from being misplanted or deviated, and the position of the esophageal stent can be monitored at any time during use, so that whether the esophageal stent is shifted can be found in time. BRIEF DESCRIPTION OF DRAWINGS

[0034] In order to more clearly illustrate the technical solutions in the embodiments of the application or the prior art, the following will briefly introduce the drawings needed to be used in the embodiments or the prior art description. Obviously, the drawings in the following description are some embodiments of the application, and other drawings can also be obtained by those skilled in the art without any creative effort on the basis of these drawings.

[0035] Figure 1 is a structural schematic diagram of an initial shape of a 4D printing esophageal stent provided by an embodiment of the application;

[0036] Figure 2 is a schematic diagram of a bionic lotus hollow structure provided by an embodiment of the application;

[0037] Figure 3 is a schematic diagram of a shape change of a recovered shape of a 4D printing esophageal stent provided by an embodiment of the application;

[0038] Figure 4 is a DSC curve diagram of shape memory polylactic acid with different tributyl citrate contents added, provided by an embodiment of the application;

[0039] Figure 51 is a DSC curve diagram of shape memory polymers with different poly(butylene adipate) / terephthalate contents provided by an embodiment of the present invention;

[0040] Figure 6 1 is a stress-strain diagram of shape memory polymers with different poly(butylene adipate) / terephthalate contents provided by an embodiment of the present invention;

[0041] Figure 7 1 is a stress-strain comparison diagram of the shape memory polymer provided by Example 1 of the present invention and Comparative Example 2;

[0042] Figure 8 is a SEM image of the shape memory polymer provided in Comparative Example 2 of the present invention;

[0043] Figure 9 is a SEM image of the shape memory polymer provided in Example 1 of the present invention;

[0044] Reference numerals:

[0045] 100-head end; 102-end; 104-middle section; 106-barb structure. DETAILED DESCRIPTION

[0046] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0047] The embodiment of the present invention provides a 4D printed esophageal stent, such as Figure 1 As shown, it includes a stent body and a drug-loaded fiber membrane with a core-shell structure; the stent body is a tubular stent composed of a bionic water lily hollow structure; the diameters of the first end 100 and the end 102 of the stent body are both larger than the diameter of the middle section 104, and the outer surfaces of the first end 100 and the end 102 are provided with barb structures 106; the stent body is a biodegradable shape memory polymer; the drug-loaded fiber membrane is located on the outer surface of the middle section 104 of the stent body, and the drug-loaded fiber membrane contains drugs.

[0048] In the embodiment of the present application, the support body adopts a bionic lotus hollow structure, which is designed with reference to the radial distribution of the leaf vein structure of lotus, thereby effectively dispersing the pressure received by the support and improving the compression resistance of the support. In addition, the support body as a whole has a dumbbell-shaped structure with thick ends and a thin middle, and the outer surfaces of the first end and the last end have barb structures, which effectively improve the anti-slippage performance of the esophageal stent. Meanwhile, the drug-loaded fiber membrane also contains drugs, which can further avoid esophageal restenosis by long-term uniform drug release, thereby ensuring the safety of the patient's life.

[0049] According to some preferred embodiments, the shape memory polymer is prepared by adding polybutylene adipate / terephthalate and tributyl citrate to shape memory polylactic acid.

[0050] According to some more preferred embodiments, the amount of polybutylene adipate / terephthalate is 2-8 wt% (for example, it can be 2 wt%, 2.5 wt%, 3 wt%, 3.5 wt%, 4 wt%, 4.5 wt%, 5 wt%, 5.5 wt%, 6 wt%, 6.5 wt%, 7 wt%, 7.5 wt% or 8 wt%) of the amount of shape memory polylactic acid, and the amount of tributyl citrate is 9-11 wt% (for example, it can be 9 wt%, 9.5 wt%, 10 wt%, 10.5 wt% or 11 wt%) of the amount of shape memory polylactic acid.

[0051] In the embodiment of the present application, the addition of polybutylene adipate / terephthalate in the above range can improve the toughness and printing performance of the material system, but the compatibility between shape memory polylactic acid and polybutylene adipate / terephthalate is poor, and the improvement of material performance is not obvious, so tributyl citrate in the above range is also added. By introducing tributyl citrate to improve the compatibility between polylactic acid and polybutylene adipate / terephthalate, the toughness and printing performance of the material system are effectively improved, the mechanical properties of the material system are more suitable for the human body, and the wear on the affected area is reduced; and further, the glass transition temperature of shape memory polylactic acid is adjusted to make the deformation temperature more suitable for the body temperature. Experiments have shown that if the content of polybutylene adipate / terephthalate is less than 2 wt% of the amount of shape memory polylactic acid, the toughness of the material system will be poor; but if it is higher than 8 wt% of the amount of shape memory polylactic acid, the compatibility between shape memory polylactic acid and polybutylene adipate / terephthalate will be worse. If the amount of tributyl citrate is less than 9 wt% of the amount of shape memory polylactic acid, the improvement of the compatibility between polylactic acid and polybutylene adipate / terephthalate is weak, and the glass transition temperature of the material system is higher than the temperature that the human body can withstand; if it is higher than 11 wt% of the amount of shape memory polylactic acid, although it can significantly improve the compatibility between polylactic acid and polybutylene adipate / terephthalate, the glass transition temperature of the material system is relatively low, which is lower than the body temperature.

[0052] According to some preferred embodiments, the esophageal stent comprises an initial shape and a temporary shape, the volume of the initial shape is greater than the volume of the temporary shape; the esophageal stent is stimulated to change from the temporary shape to the initial shape by heat driving.

[0053] It should be noted that the heat driving stimulation temperature of the esophageal stent in the present application is the glass transition temperature of the shape memory polymer. Specifically, the esophageal stent deforms into a temporary shape at the material transition temperature and restores to the initial shape under the driving condition.

[0054] According to some preferred embodiments, the shell layer of the drug-loaded fiber membrane is polycaprolactone, and the core layer is ethyl cellulose.

[0055] In the embodiments of the present application, the stent body and the drug-loaded fiber membrane are both prepared from biodegradable materials, have biocompatibility, can reduce the occurrence of rejection reactions, and effectively alleviate the pain of patients; the esophageal stent has a three-dimensional network structure, can play a supporting role at the stenosis of the esophagus of the patient after being implanted into the human body, can maintain the patency of the esophagus, and maintain the normal function of the esophagus; during the use of the esophageal stent, the esophageal stent will be gradually biodegraded into non-toxic and non-immunogenic products, which are absorbed by the human body or discharged outside the body, and the safety is higher.

[0056] According to some preferred embodiments, the drug-loaded fiber membrane contains an anti-scarring drug.

[0057] According to some preferred embodiments, the content of the anti-scarring drug accounts for 1-5wt% (for example, can be 1wt%, 1.5wt%, 2wt%, 2.5wt%, 3wt%, 3.5wt%, 4wt%, 4.5wt% or 5wt%) of the core layer of the drug-loaded fiber membrane.

[0058] According to some more preferred embodiments, the anti-scarring drug is paclitaxel.

[0059] In the embodiments of the present application, the existence of the core-shell structure of the drug-loaded fiber membrane can make the drug in the fiber membrane achieve long-term and uniform sustained release, so as to ensure that the anti-scarring drug can continuously play a role during the use of the esophageal stent, so as to prevent the phenomenon of esophageal restenosis.

[0060] In the present application, experiments have proved that if the content of the anti-scarring drug is less than 1wt% of the core layer of the drug-loaded fiber membrane, the drug dosage is too low, the drug-loaded fiber membrane with the core-shell structure carries too little drug, and the treatment effect is reduced; but if the content of the anti-scarring drug is higher than 5wt% of the core layer of the drug-loaded fiber membrane, the drug content in the drug-loaded fiber membrane is too high, which may increase the risk of side effects, and even cause local tissue damage or more serious complications.

[0061] According to some preferred embodiments, the bionic water lily hollow structure takes a regular hexagon as a framework, and the regular hexagon is divided into a plurality of rhombuses and a plurality of triangles.

[0062] In the embodiments of the present application, the framework of the regular hexagon is designed in reference to the radial distribution of the leaf vein structure of the water lily, and the leaf vein structure divides the regular hexagon into a plurality of rhombuses and a plurality of triangles, thereby effectively dispersing the pressure on the support body and improving the compression resistance of the support body.

[0063] According to some more preferred embodiments, as shown in Figure 2 the regular hexagon is divided into 10 rhombuses and 4 triangles, and the regular hexagon is an axisymmetric figure. Specifically, 6 identical rhombuses (including a first rhombus, a second rhombus, a third rhombus, a fourth rhombus, a fifth rhombus, and a sixth rhombus) are arranged at the center of the regular hexagon, and the 6 acute angles of the 6 rhombuses converge at the center and divide the 360° circumferential angle equally. The seventh rhombus is arranged between the first rhombus and the second rhombus, and the eighth rhombus is arranged between the second rhombus and the third rhombus. The first triangle and the second triangle are arranged between the third rhombus and the fourth rhombus, and the first triangle and the second triangle combine to form a rhombus. The ninth rhombus is arranged between the fourth rhombus and the fifth rhombus, the tenth rhombus is arranged between the fifth rhombus and the sixth rhombus, the third triangle and the fourth triangle are arranged between the sixth rhombus and the first rhombus, and the third triangle and the fourth triangle combine to form a rhombus. All the rhombuses are of the same size.

[0064] According to some more preferred embodiments, the side length of the regular hexagon is 1 / 12-1 / 3 (for example, 1 / 12, 1 / 11, 1 / 10, 1 / 9, 1 / 8, 1 / 7, 1 / 6, 1 / 5, 1 / 4, or 1 / 3) of the circumference of the support body.

[0065] According to some more preferred embodiments, the side length of the regular hexagon is 1 / 9 or 1 / 6 of the circumference of the support body.

[0066] In the present application, experiments have proved that if the side length of the bionic water lily hollow structure is less than 1 / 12 of the circumference of the support body, the bionic water lily hollow structures in the support body are too dense, which increases the difficulty of 4D printing. If the side length of the bionic water lily hollow structure is greater than 1 / 3 of the circumference of the support body, the number of bionic water lily hollow structures in the support body is too small, which leads to poor bearing performance of the support body and affects the performance of the esophageal stent.

[0067] According to some preferred embodiments, the acute angle of the rhombus is 50°-70° (for example, 50°, 52°, 55°, 58°, 60°, 62°, 65°, 68°, or 70°).

[0068] In the present application, it is proved by experiments that if the acute interior angle of the rhombus is less than 50°, the difficulty of 4D printing is increased; if the acute interior angle of the rhombus is greater than 70°, the support effect of the curved section of the esophageal stent is decreased when bending.

[0069] According to some preferred embodiments, the diameter of the leading end is the same as the diameter of the trailing end, and the diameter of the leading end and the trailing end is 2-4 mm (for example, it can be 2 mm, 2.5 mm, 3 mm, 3.5 mm or 4 mm) larger than the diameter of the middle section.

[0070] According to some preferred embodiments, as shown in Figure 1 The length of the barb structure 106 is 0.5-1.5 mm (for example, it can be 0.5 mm, 1 mm or 1.5 mm), and the barb angle α is 40-50° (for example, it can be 40°, 42°, 45°, 48° or 50°).

[0071] According to some more preferred embodiments, 9-18 (for example, it can be 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18) barb structures are arranged along the circumference of the leading end and the trailing end.

[0072] In the embodiment of the present application, the radius of the middle section of the stent body is similar to the radius of the diseased esophagus to which the stent body is applied, the diameter of the leading end and the trailing end is larger than the diameter of the middle section, so that the stent body is in the shape of a dumbbell, and the radius of the flared ends (i.e. the leading end and the trailing end) is 1-2 mm larger than that of the middle section. The outer surface of the flared ends has a barb structure, the length of the barb is 0.5-1.5 mm, the barb angle is 40-50°, and the number of barbs in one circle is 9-18. The existence of the flared ends and the barb structure can effectively improve the anti-migration performance of the stent without damaging the esophagus of the patient. It should be noted that the transition section connecting the two ends and the middle section is not specifically limited and can only achieve the connection of the two.

[0073] According to some preferred embodiments, the leading end and the trailing end are also provided with a developing marker.

[0074] According to some more preferred embodiments, the developing marker is one or more of gold, tungsten, platinum-iridium alloy and nickel-titanium alloy.

[0075] In the embodiment of the present application, the two ends of the stent body are also provided with developing markers, such as metal wires made of one or more of gold, tungsten, platinum-iridium alloy, nickel-titanium alloy, which are wound 2-4 turns at the two ends of the stent body; the presence of the shadow markers can avoid the misplacement or deviation of the esophageal stent, and can monitor the position of the esophageal stent at any time during use, so that the sliding of the esophageal stent can be found in time.

[0076] It should be noted that one or more is any one or any mixture of several in any proportion.

[0077] The present application also provides a preparation method of the above-mentioned 4D printed esophageal stent, which comprises:

[0078] (1) designing a three-dimensional structure model of the esophageal stent;

[0079] (2) determining the shape memory polymer used for the esophageal stent, preparing the shape memory polymer into a printing wire, and printing the printing wire by using 4D printing technology to obtain a stent body with an initial shape after forming;

[0080] (3) preparing a drug-loaded fiber membrane with a core-shell structure by using electrospinning method, and placing the drug-loaded fiber membrane on the outer surface of the middle section of the stent body to obtain a 4D printed esophageal stent.

[0081] It should be noted that the three-dimensional structure model of the 4D printed esophageal stent is collected by using human three-dimensional scanners, magnetic resonance imaging technology (MRI), CT scanning technology, etc. to collect the medical image data of the esophagus and the surrounding tissues of the patient, and the data obtained is processed by using medical simulation software, computer-aided design software, etc. to design and establish, so that the esophageal stent returned to the initial shape can better support and drug the patient's esophagus. For example, according to the actual situation of the patient, the material system, the structure parameters and the printing method suitable for the patient are selected, and the three-dimensional structure model of the esophageal stent is established.

[0082] According to some preferred embodiments, in step (2), polybutylene adipate / terephthalate, shape memory polylactic acid and tributyl citrate are added into the screw extruder, mixed and extruded to obtain the printing wire.

[0083] According to some more preferred embodiments, in order to smoothly extrude the shape memory polymer to obtain the printing wire, the speed of the screw extruder is set to 62-65 rpm (for example, it can be 62 rpm, 63 rpm, 64 rpm or 65 rpm), the temperature of the nozzle is 170-180℃ (for example, it can be 170℃, 175℃ or 180℃), the feeding speed is 5.1-5.3, and the discharge speed of tributyl citrate is 2.8-3.2 mL / min.

[0084] Specifically, the 4D printing method of the esophageal stent is a fused deposition modeling technology. The preparation method of the 4D printed esophageal stent provided by the application is used for preparing the esophageal stent by using the 4D printing technology, is not limited by a complex structure, is suitable for personalized customization of the esophageal stent, has a wide application prospect, has the characteristics of rapid prototyping, greatly shortens the preparation time of the esophageal stent mold, has low preparation cost, a simple preparation method, strong practicability, is easy to be accepted by consumers, and has significant social and economic benefits.

[0085] According to some preferred embodiments, in step (3), the polycaprolactone and the mixed solvent are mixed to obtain a shell layer spinning solution; the ethyl cellulose, the anti-scarring drug and the mixed solvent are mixed to obtain a core layer spinning solution; the shell layer spinning solution and the core layer spinning solution are respectively added to syringes, and a drug-loaded fiber membrane is obtained by using the electrospinning method through coaxial needles.

[0086] According to some more preferred embodiments, the electrospinning conditions are as follows: the flow rate of the shell layer spinning solution is 0.6-0.8 mL / h (for example, it can be 0.6 mL / h, 0.65 mL / h, 0.7 mL / h, 0.75 mL / h or 0.8 mL / h), the flow rate of the core layer spinning solution is 0.3-0.4 mL / h (for example, it can be 0.3 mL / h, 0.35 mL / h or 0.4 mL / h), the spinning voltage is 18-24 kV (for example, it can be 18 kV, 20 kV, 22 kV or 24 kV), and the spinning distance is 10-20 cm (for example, it can be 10 cm, 12 cm, 15 cm, 18 cm or 20 cm).

[0087] In the embodiments of the application, the anti-scarring drug is added in the core layer, which can delay the diffusion rate of the drug. At the same time, by limiting the flow rates of the shell layer spinning solution and the core layer spinning solution within the above range, not only the continuity of the core-shell structure can be maintained to avoid structural defects, but also the controllability of the release of the anti-scarring drug in the core layer can be ensured.

[0088] In the application, in actual application, the 4D printed esophageal stent is shaped into a temporary shape with a smaller volume at the glass transition temperature, and after being implanted into the human body in the temporary shape, the mesh structure of the esophageal stent is restored to the initial shape through a driving condition, thereby playing a supporting role.

[0089] In order to more clearly illustrate the technical solutions and advantages of the application, the following describes in detail a 4D printed esophageal stent and a preparation method thereof through several embodiments.

[0090] In the following examples and comparative examples, the electrospinning conditions are as follows: the flow rate of the shell layer spinning solution is 0.8 mL / h, the flow rate of the core layer spinning solution is 0.4 mL / h, the spinning voltage is 20 kV, and the spinning distance is 12 cm. The relative molecular mass of the shape memory polylactic acid is 43,000, the relative molecular mass of the polybutylene adipate terephthalate is 150,000, and the relative molecular mass of the polycaprolactone is 8,000. The speed of the twin-screw extruder is 62-65 rpm, the die temperature is 170-180 °C, the feeding speed is 5.1-5.3, and the tri-n-butyl citrate is discharged at a speed of 2.8-3.2 mL / min.

[0091] Example 1

[0092] The method for preparing the 4D-printed esophageal stent comprises the following steps:

[0093] S1. Selecting a material system, structure parameters, and a printing method according to the actual situation of the patient, and establishing a three-dimensional structure model of the esophageal stent according to the size and shape of the corresponding esophagus, as shown in FIGS. 1 and 2. The length of the side of the regular hexagonal frame of the bionic lotus hollow structure is 1 / 6 of the circumference of the stent body, the radius of the flared end is 1.5 mm larger than that of the middle section, the length of the barb is 1.5 mm, the angle of the barb is 45°, two circles of barbs are arranged at the first end and the last end, and the number of barbs in each circle is 18. Figure 1 Figure 2 S2. Preparing a printing wire from the determined shape memory polymer system by using a twin-screw extruder, specifically: mixing and extruding polybutylene adipate terephthalate, shape memory polylactic acid, and tri-n-butyl citrate in the screw extruder to obtain a printing wire; and preparing a customized 4D-printed stent body according to the three-dimensional structure model determined in step S1. The amount of polybutylene adipate terephthalate is 4 wt% of the amount of shape memory polylactic acid, and the amount of tri-n-butyl citrate is 10 wt% of the amount of shape memory polylactic acid.

[0094] S3. Mixing dichloromethane and dimethylacetamide to prepare a mixed solvent, mixing polycaprolactone with the mixed solvent to prepare a shell layer spinning solution, and mixing ethyl cellulose and paclitaxel with the mixed solvent to prepare a core layer spinning solution; adding the shell layer spinning solution and the core layer spinning solution into syringes, respectively, and obtaining a drug-loaded fiber membrane with a core-shell structure by using an electrospinning method through coaxial needles.

[0095] S4. Adhering the drug-loaded fiber membrane with the core-shell structure to the middle section of the material prepared in step S2 to prepare the outer surface of the middle section of the customized 4D-printed stent body, and arranging two circles of platinum-iridium alloy wires at the hollowed-out portions of the first end and the last end to obtain a customized esophageal stent with an initial shape.

[0096] S4. Adhering the drug-loaded fiber membrane with the core-shell structure to the middle section of the material prepared in step S2 to prepare the outer surface of the middle section of the customized 4D-printed stent body, and arranging two circles of platinum-iridium alloy wires at the hollowed-out portions of the first end and the last end to obtain a customized esophageal stent with an initial shape.

[0097] ​Application of the esophageal stent: the esophageal stent is shaped into a temporary shape at the glass transition temperature, after being implanted into the human body, the esophageal stent is restored to the initial shape at the diseased site of the patient through suitable driving conditions, which plays a supporting role for the stenotic lumen of the patient, maintains the patency of the lumen, and maintains the normal function of the lumen. And the drug in the drug-loaded fiber membrane with core-shell structure will be slowly released during the use of the esophageal stent, further avoiding esophageal restenosis.

[0098] Specifically, for the application of the esophageal stent, Figure 3 The shape change of the esophageal stent is shown, from left to right in turn is the temporary shape, the initial shape of the esophageal stent. After obtaining the initial shape of the esophageal stent as shown in Figure 1 After obtaining the initial shape of the esophageal stent as shown in

[0099] Example 2

[0100] The preparation method of the 4D printed esophageal stent comprises:

[0101] S1, selecting the material system, structure parameters and printing method according to the actual situation of the patient, and establishing a three-dimensional structure model of the esophageal stent according to the size and shape of the corresponding esophagus, as shown in Figure 1 and Figure 2 The length of the edge of the regular hexagonal frame of the bionic lotus hollow structure is 1 / 9 of the circumference of the stent body, the radius of the two end flares is 1.5 mm larger than that of the middle segment, the length of the barb is 1.5 mm, the angle of the barb is 45°, two circles of barbs are arranged at the first end and the last end, and the number of barbs in each circle is 18;

[0102] S2, the shape memory polymer system determined is made into a printing wire through a double screw extruder, specifically: polybutylene adipate / terephthalate shape memory polylactic acid and tributyl citrate are added to the screw extruder, mixed and extruded to obtain a printing wire; and a customized 4D printed stent body is prepared according to the three-dimensional structure model determined in step S1; the amount of polybutylene adipate / terephthalate is 2wt% of the amount of shape memory polylactic acid, and the amount of tributyl citrate is 9wt% of the amount of shape memory polylactic acid;

[0103] S3. Mixing dichloromethane and dimethylacetamide to form a mixed solvent, mixing polycaprolactone with the mixed solvent to form a shell spinning solution, and mixing ethyl cellulose and paclitaxel with the mixed solvent to form a core spinning solution; respectively adding the shell spinning solution and the core spinning solution into a syringe, and electrospinning the drug-loaded fiber membrane having a core-shell structure using a coaxial needle by a method of electrospinning, wherein the drug-loaded core-shell fiber membrane has a paclitaxel content of 5 wt %;

[0104] The drug-loaded fiber membrane with a core-shell structure is adhered to the material determined in step S2 to prepare the outer surface of the middle section of the customized 4D printed stent body, and two loops of platinum-iridium alloy wire are arranged at the hollow parts of the head and the end to obtain a customized esophageal stent with the initial shape.

[0105] Example 3

[0106] The preparation method of the 4D printed esophageal stent includes:

[0107] S1. Select the material system, structural parameters and printing method according to the actual situation of the patient, and build a three-dimensional structural model of the esophageal stent according to the size and shape of the corresponding esophagus, such as Figure 1 and Figure 2 As shown in the figure, the side length of the regular hexagonal frame used in the bionic water lily hollow structure is 1 / 6 of the circumference of the stent body, the radius of the flared openings at both ends is 1.5 mm larger than that of the middle section, the barb length is 1.5 mm, the barb angle α is 50°, and two circles of barbs are set at the head and the end, with 18 barbs in each circle.

[0108] S2. The determined shape memory polymer system is formed into a printing filament using a twin-screw extruder. Specifically, polybutylene adipate / terephthalate, shape memory polylactic acid, and tributyl citrate are added to a screw extruder, mixed, and extruded to obtain a printing filament; and a customized 4D printed stent body is prepared according to the three-dimensional structure model determined in step S1; the amount of polybutylene adipate / terephthalate is 6wt% of the amount of the shape memory polylactic acid, and the amount of tributyl citrate is 10wt% of the shape memory polylactic acid;

[0109] S3. Mixing dichloromethane and dimethylacetamide to form a mixed solvent, mixing polycaprolactone with the mixed solvent to form a shell spinning solution, and mixing ethyl cellulose and paclitaxel with the mixed solvent to form a core spinning solution; respectively adding the shell spinning solution and the core spinning solution into a syringe, and electrospinning the drug-loaded fiber membrane having a core-shell structure using a coaxial needle by a method of electrospinning, wherein the drug-loaded core-shell fiber membrane has a paclitaxel content of 5 wt %;

[0110] The drug-loaded fiber membrane with a core-shell structure is adhered to the material determined in step S2 to prepare the outer surface of the middle section of the customized 4D printed stent body, and two loops of platinum-iridium alloy wire are arranged at the hollow parts of the head and the end to obtain a customized esophageal stent with the initial shape.

[0111] Example 4

[0112] The preparation method of the 4D printed esophageal stent includes:

[0113] S1. Select the material system, structural parameters and printing method according to the actual situation of the patient, and build a three-dimensional structural model of the esophageal stent according to the size and shape of the corresponding esophagus, such as Figure 1 and Figure 2 As shown in the figure, the side length of the regular hexagonal frame used in the bionic water lily hollow structure is 1 / 6 of the circumference of the bracket body, the radius of the flared opening at both ends is 1mm larger than that of the middle section, the barb length is 1mm, the barb angle α is 50°, and two circles of barbs are set at the head and the end, with 18 barbs in each circle.

[0114] S2. The determined shape memory polymer system is formed into a printing filament using a twin-screw extruder. Specifically, polybutylene adipate / terephthalate, shape memory polylactic acid, and tributyl citrate are added to a screw extruder, mixed, and extruded to obtain a printing filament; and a customized 4D printed stent body is prepared according to the three-dimensional structural model determined in step S1; the amount of polybutylene adipate / terephthalate is 8wt% of the amount of the shape memory polylactic acid, and the amount of tributyl citrate is 11wt% of the shape memory polylactic acid.

[0115] S3. Mixing dichloromethane and dimethylacetamide to form a mixed solvent, mixing polycaprolactone with the mixed solvent to form a shell spinning solution, and mixing ethyl cellulose and paclitaxel with the mixed solvent to form a core spinning solution; respectively adding the shell spinning solution and the core spinning solution into a syringe, and electrospinning the drug-loaded fiber membrane having a core-shell structure using a coaxial needle by a method of electrospinning, wherein the drug-loaded core-shell fiber membrane has a paclitaxel content of 5 wt %;

[0116] The drug-loaded fiber membrane with a core-shell structure is adhered to the material determined in step S2 to prepare the outer surface of the middle section of the customized 4D printed stent body, and two loops of platinum-iridium alloy wire are arranged at the hollow parts of the head and the end to obtain a customized esophageal stent with the initial shape.

[0117] Example 5

[0118] The preparation method of the 4D printed esophageal stent includes:

[0119] S1, selecting a material system, structure parameters and printing method according to the actual situation of the patient, and establishing a three-dimensional structure model of the esophageal stent according to the size and shape of the corresponding esophagus, as shown in Figure 1 and Figure 2 The length of the edge of the regular hexagonal frame adopted by the bionic water lily hollow structure is 1 / 6 of the circumference of the stent body, the radius of the two end flares is 1.5 mm larger than that of the middle section, the length of the barb is 1.5 mm, the barb angle a is 45°, two circles of barbs are arranged at the first end and the last end, and the number of barbs in each circle is 12;

[0120] S2, the shape memory polymer system determined is made into a printing wire by a double screw extruder, specifically: polybutylene adipate terephthalate, shape memory polylactic acid and tributyl citrate are added to the screw extruder, mixed and extruded to obtain a printing wire; and a customized 4D printed stent body is prepared according to the three-dimensional structure model determined in step S1; the amount of polybutylene adipate terephthalate is 4wt% of the amount of shape memory polylactic acid, and the amount of tributyl citrate is 10wt% of the amount of shape memory polylactic acid;

[0121] S3, dichloromethane and dimethylacetamide are mixed to prepare a mixed solvent, polycaprolactone is mixed with the mixed solvent to prepare a shell layer spinning solution, ethyl cellulose and paclitaxel are mixed with the mixed solvent to prepare a core layer spinning solution; the shell layer spinning solution and the core layer spinning solution are added to syringes respectively, and a drug-loaded fiber membrane with a core-shell structure is obtained by electrospinning through coaxial needles, wherein the content of paclitaxel in the drug-loaded core-shell fiber membrane is 1wt%;

[0122] The drug-loaded fiber membrane with a core-shell structure is adhered to the outer surface of the middle section of the customized 4D printed stent body prepared from the material determined in step S2, and two circles of platinum-iridium alloy wires are arranged at the hollow parts of the first end and the last end, to obtain a customized esophageal stent with an initial shape.

[0123] Example 6

[0124] Example 6 is basically the same as Example 1, except that the content of polybutylene adipate terephthalate in step S2 is different;

[0125] Specifically, the amount of polybutylene adipate terephthalate is 2wt% of the amount of shape memory polylactic acid, and the amount of tributyl citrate is 10wt% of the amount of shape memory polylactic acid.

[0126] Example 7

[0127] Example 7 is basically the same as Example 1, except that the content of polybutylene adipate terephthalate in step S2 is different;

[0128] Specifically, the amount of polybutylene adipate terephthalate is 8wt% of the amount of shape memory polylactic acid, and the amount of tributyl citrate is 10wt% of the amount of shape memory polylactic acid.

[0129] Comparative Example 1

[0130] Comparative Example 1 is basically the same as Example 1, except that no polybutylene adipate terephthalate is added in step S2.

[0131] Comparative Example 2

[0132] Comparative Example 2 is basically the same as Example 1, except that no tributyl citrate is added in step S2.

[0133] Figure 4 The DSC curve of shape memory polylactic acid with different amounts of tributyl citrate is shown, and it can be seen from Figure 4 that when the amount of tributyl citrate is between 9wt% and 11wt% of the shape memory polylactic acid, the glass transition temperature of the shape memory polylactic acid with tributyl citrate is between 38.2℃ and 44.7℃, but when the amount of tributyl citrate is 8wt% of the shape memory polylactic acid, the glass transition temperature of the system is 47.8℃, which exceeds the temperature that the human body can withstand; when the amount of tributyl citrate is 12wt% of the shape memory polylactic acid, the glass transition temperature of the system is as low as 34.3℃, which is lower than the human body temperature, and since the stent will restore to the initial shape after entering the human body, the problem of the esophageal stent restoring to the initial shape in a non-affected part may occur. It should be noted that Figure 4 PLA / x%TBC in the above table represents shape memory polylactic acid with xwt% tributyl citrate, and the amount of tributyl citrate is xwt% of the shape memory polylactic acid.

[0134] Figure 5 The DSC curves of shape memory polymers with different amounts of polybutylene adipate terephthalate are shown, and it can be seen from Figure 4 and Figure 5 that the introduction of polybutylene adipate terephthalate does not change the glass transition temperature of the system, and it can be seen from Figure 5 that the amount of polybutylene adipate terephthalate has little effect on the shape memory polymer, and the glass transition temperature of the shape memory polymer is about 40℃, which is closer to the human body temperature.

[0135] Figure 6 The stress-strain curves of shape memory polymers with different amounts of polybutylene adipate terephthalate are shown, and it can be seen from Figure 6It can be seen that the introduction of polybutylene adipate terephthalate improves the toughness of the shape memory polylactic acid, and when the amount of polybutylene adipate terephthalate is 2-8wt% of the amount of the shape memory polylactic acid, the shape memory polymer has excellent toughness.

[0136] Figure 7 The stress-strain curves of the shape memory polymers provided by Example 1 and Comparative Example 2 are shown, and it can be seen that the addition of tributyl citrate improves the compatibility of the shape memory polylactic acid and polybutylene adipate terephthalate.

[0137] Figure 8 、 Figure 9 The SEM images of the shape memory polymers in Comparative Example 2 and Example 1 are shown, respectively, and it can be seen that the shape memory polylactic acid and polybutylene adipate terephthalate are not compatible. Figure 8 It can be seen that the shape memory polylactic acid and polybutylene adipate terephthalate are not compatible. Figure 9 It can be seen that the addition of tributyl citrate improves the compatibility of the shape memory polylactic acid and polybutylene adipate terephthalate.

[0138] The radial support force of the 4D printed esophageal stent prepared in Example 1 at each temperature was tested, and it was found that the radial support force of the 4D printed esophageal stent at room temperature (25℃) was 2.113N / mm, the radial support force at 36℃ was 0.821N / mm, the radial support force at 37℃ was 0.74N / mm, the radial support force at 38℃ was 0.476N / mm, the radial support force at 39℃ was 0.444N / mm, and the radial support force at 40℃ was 0.334N / mm; wherein the radial support force is the force supported when the stent is compressed to 50% of the initial diameter. The glass transition temperature of the 4D printed esophageal stent was 41.8℃.

[0139] Based on the existing stents described in the document entitled A novel biodegradable esophageal stent: results from mechanical and animal experiments by Liu J, Shang L, Liu J et al. published in American Journal of Translational Research in 2016, it can be found that the radial support force of the wall stent (Wall stent) is 0.172 N / mm, the radial support force of the ZA stent is 0.095 N / mm, the radial support force of the Accucflex stent is 0.065 N / mm, the radial support force of the smart stent (SMART stent) is 0.093 N / mm, the radial support force of the spiral Z-type stent is 0.112 N / mm, and the radial support force of the NT stent is 0.051 N / mm, all of which are much lower than the 2.113 N / mm of the esophageal stent of Example 1, thus further confirming that the esophageal stent prepared in the present application has excellent compression load capacity.

[0140] It should be noted that, Figure 5 and Figure 6 PLA in the above-mentioned examples and comparative examples is pure shape memory polylactic acid, PLA / 10%TBC corresponds to the shape memory polymer prepared in Comparative Example 1, PLA / 10%TBC / 2%PBAT corresponds to the shape memory polymer prepared in Example 6, PLA / 10%TBC / 4%PBAT corresponds to the shape memory polymer prepared in Example 1, PLA / 10%TBC / 6%PBAT corresponds to the shape memory polymer prepared in Example 3, and PLA / 10%TBC / 8%PBAT corresponds to the shape memory polymer prepared in Example 7. Figure 7 PLA / 4PBAT in the above-mentioned examples and comparative examples corresponds to the shape memory polymer prepared in Comparative Example 2, and PLA / 10TBC / 4PBAT corresponds to the shape memory polymer prepared in Example 1.

[0141] By comparing the application examples and the above-mentioned Comparative Examples 1 to 6 of the 4D printed esophageal stents, it can be found that the 4D printed esophageal stent prepared in the application examples has excellent compression load capacity and anti-slippage capacity, and the drug-loaded fiber membrane can avoid esophageal restenosis by long-term uniform drug release, thereby ensuring the safety of patients' lives.

[0142] It should be pointed out finally that the above embodiments are only used to illustrate the technical solutions of the present application, but not to limit the same; and although the present application has been described in detail with reference to the foregoing embodiments, it should be appreciated by those skilled in the art that the technical solutions recorded in the foregoing embodiments can be modified, or some technical features thereof can be replaced equivalently; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the spirit and scope of the technical solutions of the embodiments of the present application.

Claims

1. A 4D-printed esophageal stent, characterized in that, The esophageal stent comprises a stent body and a drug-loaded fiber membrane with a core-shell structure; the stent body is a tubular stent composed of a bionic lotus hollow structure; the diameters of the head end and the tail end of the stent body are both larger than the diameter of the middle section, and the outer surfaces of the head end and the tail end are both provided with barb structures; the stent body is a biodegradable shape memory polymer; the drug-loaded fiber membrane is located on the outer surface of the middle section of the stent body, and the drug-loaded fiber membrane contains drugs.

2. The 4D-printed esophageal stent of claim 1, wherein, The shape memory polymer is prepared by adding polybutylene adipate terephthalate and tributyl citrate to shape memory polylactic acid; preferably, the amount of polybutylene adipate terephthalate is 2-8 wt% of the amount of shape memory polylactic acid, and the amount of tributyl citrate is 9-11 wt% of the amount of shape memory polylactic acid.

3. The 4D-printed esophageal stent of claim 1, wherein, The shell layer of the drug-loaded fiber membrane is polycaprolactone, and the core layer is ethyl cellulose; and / or, The drug-loaded fiber membrane contains an anti-scarring drug; preferably, the content of the anti-scarring drug is 1-5 wt% of the core layer of the drug-loaded fiber membrane.

4. The 4D-printed esophageal stent of claim 1, wherein, The bionic lotus hollow structure takes a regular hexagon as a frame, and the regular hexagon is divided into several rhombuses and several triangles; preferably, the side length of the regular hexagon is 1 / 12-1 / 3 of the circumference of the stent body.

5. The 4D-printed esophageal stent of claim 4, wherein, The regular hexagon is divided into 10 rhombuses and 4 triangles, and the regular hexagon is an axisymmetric figure; and / or, The acute internal angle of the rhombus is 50-70°.

6. The 4D-printed esophageal stent of claim 1, wherein, The diameter of the head end is the same as the diameter of the tail end, and the diameters of the head end and the tail end are both 2-4 mm larger than the diameter of the middle section; and / or, The length of the barb structure is 0.5-1.5 mm, and the barb angle is 40-50°; preferably, 9-18 barb structures are arranged along the circumferences of the head end and the tail end.

7. The 4D-printed esophageal stent according to any one of claims 1 to 6, wherein, The head end and the tail end are also provided with a developing marker; preferably, the developing marker is one or more of gold, tungsten, platinum-iridium alloy, and nickel-titanium alloy; and / or, The esophageal stent comprises an initial shape and a temporary shape, and the volume of the initial shape is larger than the volume of the temporary shape; the esophageal stent is deformed from the temporary shape to the initial shape by thermal driving stimulation.

8. A method of preparing the 4D-printed esophageal stent according to any one of claims 1 to 7, characterized in that, The preparation method comprises: (1) designing a three-dimensional structure model of an esophageal stent; (2) determining a shape memory polymer used by the esophageal stent, preparing a printing wire material from the shape memory polymer, printing the printing wire material by using a 4D printing technology, and obtaining a stent body with an initial shape after molding; (3) preparing a drug-loaded fiber membrane with a core-shell structure by using an electrostatic spinning method, and placing the drug-loaded fiber membrane on the outer surface of the middle section of the stent body to obtain the 4D printed esophageal stent.

9. The production method according to claim 8, characterized by, In step (2), polybutylene adipate terephthalate, shape memory polylactic acid, and tributyl citrate are added to a screw extruder, uniformly mixed, and extruded to obtain the printing wire material; preferably, the speed of the screw extruder is 62-65 rpm, and the temperature is 170-180°C.

10. The production method according to claim 8 or 9, characterized by, In step (3), The polycaprolactone and mixed solvents are mixed to obtain a shell spinning solution; the ethyl cellulose, anti-scarring drug and mixed solvents are mixed to obtain a core spinning solution; the shell spinning solution and the core spinning solution are respectively added into syringes, and the drug-loaded fiber membrane is obtained by using an electrospinning method through coaxial needles; wherein the mixed solvents comprise dichloromethane and dimethylacetamide; preferably, the electrospinning conditions are as follows: the flow rate of the shell spinning solution is 0.6-0.8 mL / h, the flow rate of the core spinning solution is 0.3-0.4 mL / h, the spinning voltage is 18-24 kV, and the spinning distance is 10-20 cm.

Citation Information

Cited By

  • Shape memory polymer fiber membrane and preparation method thereof, shape memory polymer scaffold and preparation method and application thereof

    CN121197519A